Participated · Equity · Aug 2026

Incorporated in 2000 and based in Goa, Molbio Diagnostics develops and manufactures the Truenat point-of-care PCR platform and test kits for molecular diagnosis across more than 30 diseases including tuberculosis, COVID, HIV, HPV and hepatitis B and C. Its battery-operated Truenat platform is patented in over 100 countries and is designed for deployment in resource-limited settings to enable decentralized diagnosis within an hour. The company operates six manufacturing facilities in India (two in Goa, two in Bengaluru, and one each in Visakhapatnam and Pune) with an installed capacity of 5,400 devices per annum and 3.9 crore Truenat test kits annually as of March 31, 2026. Financially, Molbio reported revenue from operations of ₹1,445 crore and profit of ₹164 crore for fiscal 2026. The company intends to expand R&D and manufacturing capacity using proceeds from its IPO, including funds earmarked for a Centre of Excellence, additional infrastructure and new plant and machinery. Its shares are proposed to be listed on the BSE and NSE on August 17, 2026.

Participated · Equity · Jun 2026

Turtlemint is positioned as an insurtech firm preparing to go public via an IPO scheduled to open on June 19, 2026. As part of the IPO process the company secured ₹397.20 crore from anchor investors at a price of ₹152 per share. The planned IPO aims to raise total proceeds of ₹883 crore, which includes an offer-for-sale component of ₹221 crore. The anchor allocation comprised 26.13 million equity shares, with a substantial portion (11.11 million shares) allotted to domestic mutual fund schemes. The company has engaged ICICI Securities, Jefferies India, JM Financial and Motilal Oswal as book-running lead managers for the offering. No additional operational metrics or financial performance figures were disclosed in the article.

Participated · Equity · Dec 2025

ICICI Prudential AMC is the asset-management subsidiary of ICICI Bank, partnering with UK-based Prudential Corporation Holdings. The firm manages a diversified suite of mutual funds and other investment products for retail and institutional clients. To prepare for a public listing, the company completed a sizeable pre-IPO round and has now set a ₹2,061–2,165 per-share price band for its upcoming ₹10,602-crore initial public offering, which will run from 12-16 December with listing expected on 19 December. The planned IPO is structured entirely as an offer-for-sale of over 4.89 crore shares by Prudential, so the company itself will not receive those proceeds. The pre-IPO equity placement valued the AMC at roughly ₹1.07 lakh crore (US $11.9 billion), highlighting strong investor demand. Post-placement, ICICI Bank increased its stake to 53 percent, while Prudential’s share will be correspondingly reduced ahead of the IPO. On listing, ICICI Prudential AMC will become the fifth asset-management firm and the fifth ICICI Group entity to trade on Indian exchanges.

Participated · Equity · Dec 2025

Founded in 2016, Wakefit has built a full-stack model that spans product design, in-house manufacturing, distribution, and customer engagement. Its portfolio covers mattresses, furniture, and home furnishings sold via its website, company-owned–company-operated (COCO) stores, and major e-commerce and multi-brand outlets. Wakefit operates five manufacturing facilities across Karnataka, Tamil Nadu, and Haryana that use imported machinery and automation to streamline production and reduce waste. For the six months ended 30 September 2025, the company generated ₹724 crore in revenue from operations and ₹35.5 crore in profit. Management plans to deploy fresh capital to open 117 new COCO stores, purchase new equipment, fund lease payments for existing outlets, and bolster marketing. The firm is preparing for a ₹1,289 crore IPO that would value it at roughly ₹6,400 crore. Wakefit’s growth trajectory positions it among the fastest Indian home-and-furnishings brands to surpass ₹1,000 crore in total income within the organised segment.

Participated · Equity · Oct 2025

Lenskart operates as a multi-category eyewear retailer, offering prescription eyeglasses, sunglasses and contact lenses under its own brand. The company caters to customers looking for affordable and stylish vision-care products. In preparation for its public listing, Lenskart has set an IPO price band of ₹382–₹402 per share. Ahead of the IPO, it has already secured significant capital through an anchor allocation, reflecting institutional confidence in the business. While detailed revenue or user metrics were not disclosed, the sizable anchor book suggests robust market interest and expectations for continued growth. The upcoming IPO will provide additional capital for expansion and operational initiatives once the public issue is completed.